{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:08:46Z","timestamp":1779210526303,"version":"3.51.4"},"reference-count":22,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Computational and Mathematical Methods in Medicine"],"published-print":{"date-parts":[[2022,3,9]]},"abstract":"<jats:p>Objective. To investigate the differences in uric acid (UA), interleukin-6 (IL-6), and free prostatic-specific antigen (fPSA)\/total prostatic-specific antigen (tPSA) (F\/T) between patients with and without prostate cancer (PCa) in order to discover the value of the three indicators in improving PCa diagnostic accuracy. Methods. Patients with pathologically diagnosed PCa (PCa group, <jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>n<\/a:mi>\n                        <a:mo>=<\/a:mo>\n                        <a:mn>25<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>), patients with other benign prostate diseases (benign group, <jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>n<\/c:mi>\n                        <c:mo>=<\/c:mo>\n                        <c:mn>25<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>), and men who underwent normal physical examination (control group, <jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>n<\/e:mi>\n                        <e:mo>=<\/e:mo>\n                        <e:mn>25<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>) at the First Affiliated Hospital of Guangzhou University of Chinese Medicine between October 2020 and January 2021 were included. The serum UA, IL-6, and F\/T levels of participants in the three groups were measured, and the measured data were statistically analyzed. Results. There were statistically significant differences in IL-6 and F\/T among the three groups (all <jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                        <g:mo>&lt;<\/g:mo>\n                        <g:mn>0.05<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>), but there were no statistically significant differences in UA (<jats:inline-formula>\n                     <i:math xmlns:i=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M5\">\n                        <i:mi>P<\/i:mi>\n                        <i:mo>&gt;<\/i:mo>\n                        <i:mn>0.05<\/i:mn>\n                     <\/i:math>\n                  <\/jats:inline-formula>). The area under the receiver operating characteristic (ROC) curve (AUC) for the three indicators was, respectively, as follows: PCa group-benign group 0.5416, 0.6776, and 0.6832; PCa group-control group 0.5432, 0.9536, and 0.9887; and benign group-control group 0.5000, 0.8784, and 0.9456. Logistic regression analysis indicated that IL-6 and F\/T were independent predictors of PCa, with AUCs of 0.6776 and 0.6832, respectively, and a combined accuracy of 72.0%. Conclusion. These results suggest that IL-6 and F\/T have a good detection effect for PCa screening. Compared with the detection of F\/T alone, the combined detection of IL-6 and F\/T can improve the diagnosis rate of PCa to a certain extent, providing effective guidance for the clinical diagnosis and treatment of patients. The value of UA needs to be further studied, and its feasibility in the diagnosis of PCa needs to be further explored.<\/jats:p>","DOI":"10.1155\/2022\/8542376","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T21:20:08Z","timestamp":1646860808000},"page":"1-5","source":"Crossref","is-referenced-by-count":6,"title":["Exploration of the Value of Combined UA, IL-6, and fPSA\/tPSA in the Diagnosis of Prostate Cancer"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7609-2517","authenticated-orcid":true,"given":"Qionghua","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijiang","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"issue":"1","key":"1","first-page":"7","article-title":"Cancer statistics","volume":"67","author":"R. L. Siegel","year":"2017","journal-title":"CA:Cancer Journal for Clinicians"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-019-0145-1"},{"key":"3","unstructured":"ShujunH.Analysis of the status and trends of prostate cancer incidence and mortality in China2015Peking Union Medical College"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14791"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2012.192"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0813-4"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5873056"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1007\/s13193-012-0142-6"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.08.005"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3710"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8778"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt017"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S257769"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-014-0408-0"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.5173\/ceju.2018.1619"},{"key":"16","volume-title":"A clinical study on the correlation between serum uric acid level and prostate cancer","author":"Z. Xue","year":"2019"},{"issue":"14","key":"17","first-page":"2214","article-title":"The expression and clinical significance of IL-4 and IL-6 in prostate cancer","volume":"26","author":"Y. Mu","year":"2018","journal-title":"Journal of Modern Oncology"},{"issue":"11","key":"18","first-page":"1229","article-title":"The progress of interleukin 6 in the development of prostate cancer","volume":"29","author":"W. Zhang","year":"2017","journal-title":"Journal of Medical Postgraduates"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13658"},{"key":"20","article-title":"CSCO prostate cancer diagnosis and treatment guide","volume-title":"Guidelines Working Committee of Chinese society of Clinical Oncology","year":"2020"},{"issue":"5","key":"21","first-page":"516","article-title":"Advances in the study of correlations between interleukin 6 and prostate cancer","volume":"22","author":"W. Luo","year":"2020","journal-title":"Military Medical Journal of Southeast China"},{"issue":"1","key":"22","first-page":"112","article-title":"Changes in serum uric acid levels and clinical significance in elderly prostate cancer patients","volume":"40","author":"J. Li","year":"2021","journal-title":"Chinese Journal of Geriatrics"}],"updated-by":[{"DOI":"10.1155\/2023\/9839167","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"record-id":"59943"},{"DOI":"10.1155\/2023\/9839167","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000}}],"container-title":["Computational and Mathematical Methods in Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/8542376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/8542376.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cmmm\/2022\/8542376.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T21:20:21Z","timestamp":1646860821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/cmmm\/2022\/8542376\/"}},"subtitle":[],"editor":[{"given":"Osamah Ibrahim","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":22,"alternative-id":["8542376","8542376"],"URL":"https:\/\/doi.org\/10.1155\/2022\/8542376","relation":{"retraction":[{"id-type":"doi","id":"10.1155\/2023\/9839167","asserted-by":"object"}]},"ISSN":["1748-6718","1748-670X"],"issn-type":[{"value":"1748-6718","type":"electronic"},{"value":"1748-670X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,9]]}}}